Patents by Inventor Olivier NEGRE

Olivier NEGRE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SICKLED BETA GLOBIN ANTIBODIES
    Publication number: 20230279145
    Abstract: The invention provides anti-?S globin antibodies or antigen binding fragments thereof.
    Type: Application
    Filed: December 22, 2022
    Publication date: September 7, 2023
    Inventor: Olivier Negre
  • Sickled beta globin antibodies
    Patent number: 11535681
    Abstract: The invention generally provides improved anti-sickled-globin antibodies and fragments thereof. In particular embodiments, the antibody or antigen binding fragment thereof recognizes the ?s, Glu6Val mutation. In various embodiments, the invention provides a conjugate comprising an anti-?s-globin antibody or antigen binding fragment thereof and a detectable label. In particular embodiments, a hybridoma comprising an anti-?s-globin antibody contemplated herein is provided.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: December 27, 2022
    Assignee: Bluebird Bio, Inc.
    Inventor: Olivier Negre
  • VCN enhancer compositions and methods of using the same
    Patent number: 11326183
    Abstract: The invention provides improved gene therapy methods and compositions. In particular embodiments, gene therapies comprise hematopoietic stem and progenitor cell compositions with increased therapeutic efficacy and methods of making and using the same. In other particular embodiments, the present invention contemplates compositions and methods for increasing transduction efficiency and vector copy number (VCN) of human hematopoietic stem and progenitor cells (HSPCs) to yield improved gene therapy compositions. In various embodiments, the present invention contemplates, in part, a population of HSPCs transduced with a lentiviral vector. In various embodiments, the present invention contemplates a method of treating sickle cell disease in a subject comprising administering the subject an effective amount of the population of hematopoietic cells contemplated herein.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: May 10, 2022
    Assignee: bluebird bio, Inc.
    Inventors: Melissa Bonner, Olivier Negre, Christopher Tipper
  • SICKLED BETA GLOBIN ANTIBODIES
    Publication number: 20200347150
    Abstract: The invention generally provides improved anti-sickled-globin antibodies and fragments thereof. In particular embodiments, the antibody or antigen binding fragment thereof recognizes the ?s, Glu6Val mutation. In various embodiments, the invention provides a conjugate comprising an anti-?s-globin antibody or antigen binding fragment thereof and a detectable label. In particular embodiments, a hybridoma comprising an anti-?s-globin antibody contemplated herein is provided.
    Type: Application
    Filed: December 14, 2018
    Publication date: November 5, 2020
    Applicant: bluebird bio, Inc.
    Inventor: Olivier NEGRE
  • VCN ENHANCER COMPOSITIONS AND METHODS OF USING THE SAME
    Publication number: 20190284533
    Abstract: The invention provides improved gene therapy methods and compositions.
    Type: Application
    Filed: February 10, 2017
    Publication date: September 19, 2019
    Applicant: bluebird bio, Inc.
    Inventors: Melissa BONNER, Olivier NEGRE
  • Gene therapy methods
    Patent number: 10280435
    Abstract: The present invention generally provides improved gene therapy vectors, cell-based compositions, and methods of using the same in methods of gene therapy. The present invention further provides improved gene therapy compositions for expanding hematopoietic cells and related methods for treatment of diseases, disorders, and conditions of the hematopoietic system such as thalassemias and anemias.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: May 7, 2019
    Assignee: bluebird bio, Inc.
    Inventors: Olivier Negre, Emmanuel Payen, Philippe Leboulch, Yves Beuzard
  • VCN ENHANCER COMPOSITIONS AND METHODS OF USING THE SAME
    Publication number: 20190078059
    Abstract: The invention provides improved gene therapy methods and compositions. In particular embodiments, gene therapies comprise hematopoietic stem and progenitor cell compositions with increased therapeutic efficacy and methods of making and using the same. In other particular embodiments, the present invention contemplates compositions and methods for increasing transduction efficiency and vector copy number (VCN) of human hematopoietic stem and progenitor cells (HSPCs) to yield improved gene therapy compositions. In various embodiments, the present invention contemplates, in part, a population of HSPCs transduced with a lentiviral vector. In various embodiments, the present invention contemplates a method of treating sickle cell disease in a subject comprising administering the subject an effective amount of the population of hematopoietic cells contemplated herein.
    Type: Application
    Filed: February 10, 2017
    Publication date: March 14, 2019
    Applicant: bluebird bio, Inc.
    Inventors: Melissa BONNER, Olivier NEGRE, Christopher TIPPER
  • GENE THERAPY METHODS
    Publication number: 20180201952
    Abstract: The present invention generally provides improved gene therapy vectors, cell-based compositions, and methods of using the same in methods of gene therapy. The present invention further provides improved gene therapy compositions for expanding hematopoietic cells and related methods for treatment of diseases, disorders, and conditions of the hematopoietic system such as thalassemias and anemias.
    Type: Application
    Filed: October 9, 2017
    Publication date: July 19, 2018
    Applicant: bluebird bio, Inc.
    Inventors: Olivier NEGRE, Emmanuel PAYEN, Philippe LEBOULCH, Yves BEUZARD